Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer von Witteveen, Petronella O., van der Mijn, Koen J.C., Los, Maartje, Kronemeijer, Roelien H., Groenewegen, Gerard, Voest, Emile E.

Volltext

A0838 - Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place von Jurascheck, L., Fransen Van De Putte, E., Van Den Brink, L., Van Der Mijn, J.C., Wilgenhof, S., Van Thienen, J.V., Haanen, J.B.A.G., Boleti, E., Powles, T., Zondervan, P.J., Graafland, N.M., Bex, A.

Volltext

Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place von Jurascheck, L., Fransen Van De Putte, E., Van Den Brink, L., Van Der Mijn, J.C., Wilgenhof, S., Van Thienen, J.V., Haanen, J.B.A.G., Boleti, E., Powles, T., Zondervan, P.J., Graafland, N.M., Bex, A.

Volltext

A0327 - Deferred cytoreductive nephrectomy following response to ipilimumab/nivolumab, is there potential for a treatment-free interval? von Fransen van de Putte, E.E., Van Den Brink, L., Mansour, M., Van Der Mijn, J.C., Wilgenhof, S., Van Thienen, J.V., Haanen, J.B.A., Boleti, E., Powles, T., Zondervan, P.J., Graafland, N.M., Bex, A.

Volltext

Deferred cytoreductive nephrectomy following response to ipilimumab/nivolumab, is there potential for a treatment-free interval? von Fransen van de Putte, E.E., Van Den Brink, L., Mansour, M., Van Der Mijn, J.C., Wilgenhof, S., Van Thienen, J.V., Haanen, J.B.A., Boleti, E., Powles, T., Zondervan, P.J., Graafland, N.M., Bex, A.

Volltext

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor–driven Programs von Linder, Simon, Severson, Tesa M., van der Mijn, Koen J.C., Nevedomskaya, Ekaterina, Siefert, Joseph C., Stelloo, Suzan, Pomerantz, Mark M., Freedman, Matthew L., van der Poel, Henk, Jerónimo, Carmen, Henrique, Rui, Bergman, Andries M., Zwart, Wilbert

Volltext

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse von Chen, Mengnuo, Mainardi, Sara, Lieftink, Cor, Velds, Arno, de Rink, Iris, Yang, Chen, Kuiken, Hendrik J., Morris, Ben, Edwards, Finn, Jochems, Fleur, van Tellingen, Olaf, Boeije, Manon, Proost, Natalie, Jansen, Robin A., Qin, Shifan, Jin, Haojie, Koen van der Mijn, J.C., Schepers, Arnout, Venkatesan, Subramanian, Qin, Wenxin, Beijersbergen, Roderick L., Wang, Liqin, Bernards, René

Volltext

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options von Zuur, Lotte G, de Barros, Hilda A, van der Mijn, Koen J C, Vis, André N, Bergman, Andries M, Pos, Floris J, van Moorselaar, Jeroen A, van der Poel, Henk G, Vogel, Wouter V, van Leeuwen, Pim J

Volltext

Supplementary Material for: Irinotecan-Induced Dysarthria von Dressel, A.J., Van Der Mijn, J.C., Aalders, I.J., Rinkel R.N.P.M., Van Der Vliet, H.J.

Volltext bestellen